Elsevier

The Lancet Oncology

Volume 11, Issue 7, July 2010, Pages 679-684
The Lancet Oncology

Review
Male hypogonadism associated with advanced cancer: a systematic review

https://doi.org/10.1016/S1470-2045(10)70021-8Get rights and content

Summary

Male hypogonadism is commonly diagnosed on the basis of subphysiological concentrations of androgen hormones, and is associated with many symptoms present in advanced cancer. Androgen deficiency might be an important cause of muscle wasting in both cancer cachexia and sarcopenia. We did a systematic review of the clinical association of male hypogonadism in advanced cancer. We searched PubMed, Medline, and Embase for publications on the relation between male hypogonadism and functional status, nutritional status, body composition, symptoms, and quality of life in patients with advanced cancer. Of 381 publications identified, six original articles were included. We found no definitive association between nutritional, functional, or quality-of-life characteristics and male hypogonadism. Possible associations between male hypogonadism and weight loss, low albumin, low-body cell mass index, low-peripheral fat and muscle mass, higher inflammation, higher pain, higher opioid consumption, worse scores for anxiety, depression, and emotional and functional well-being need to be confirmed by better designed studies. There is no clear epidemiological data to indicate whether male hypogonadism is independently associated with clinical and biological sequelae of cancer cachexia, such as higher inflammation, fatigue, and body wasting. Standardised kits sensitive to low concentrations of free-testosterone or bioavailable testosterone are needed to diagnose androgen deficiency in women. A clearer epidemiology of androgen deficiencies in advanced cancer will help determine which patients should receive testosterone-replacement therapy for alleviating cancer cachexia symptoms and improving quality of life.

Introduction

Male hypogonadism is characterised by the presence of low concentrations of circulating androgen hormones, namely testosterone.1 Subphysiological concentrations of testosterone or androgen deficiency can also be present in women, as a result of abnormal ovarian, adrenal, and peripheral tissue functions.1 However, the normal androgen concentrations in women have not been established, and diagnosis of deficiency in women is complex. The Endocrine Society guidelines suggest that no established definition of androgen deficiency in women exists on which to base clinical care. Such definition presupposes standard, valid assays and normative data that are only now being developed.2 Our review, therefore, focuses only on androgen deficiency in men or male hypogonadism associated with advanced cancer.

Male hypogonadism results from the failure of the testes to produce physiological concentrations of testosterone, and is caused by a disruption in one or more levels within the hypothalamic–pituitary–gonadal axis.3 Primary hypogonadism or primary testicular failure relates to testicular dysfunction, characterised by high amounts of gonadotropins, particularly luteinising hormone.3 Luteinising hormone is produced by the pituitary gland and acts on the Leydig cells in the testes to stimulate the production of testosterone, which controls the release of luteinising hormone via a feedback mechanism.4 Secondary hypogonadism relates to a central defect of hypothalamus or pituitary gland, which causes secondary testicular failure and is commonly diagnosed on the basis of low, or low to normal amounts of luteinising hormone.3 In male patients with cancer, primary hypogonadism can be associated with chemotherapy and higher concentrations of ghrelin or interleukin 6, whereas secondary hypogonadism is associated with higher opioid consumption and high concentrations of ghrelin.5

Male hypogonadism is normally diagnosed on the basis of low concentrations of total testosterone, free testosterone, and bioavailable testosterone, or any combination of these three values. Total testosterone is the typical measure and is defined as the sum of unbound and protein-bound testosterone in circulation.3 Protein-bound testosterone is bound to either sex-hormone-binding globulin (44%) or albumin (about 50%).6 The remaining testosterone is unbound or free testosterone, and makes up about 0·5–3·0% of that in circulation.7 Because testosterone bound to albumin is readily dissociable, it is bioavailable. Another common measure of testosterone is bioavailable testosterone, which is the sum of unbound testosterone and testosterone loosely bound to albumin.7

Symptoms such as diminished energy, poor concentration, depression, sleep disturbances, decreased physical performance (ability to accomplish tasks that require physical attributes such as muscle strength and endurance for prolonged efforts), fatigue, and weakness have been associated with male hypogonadism.8, 9, 10, 11, 12, 13 Moreover, a reduction in testosterone might lead to reduced bone mass, muscle strength, and sexual function and desire in both men and women.14, 15 Up to 50% of men with advanced cancer can present with low concentrations of testosterone before receiving chemotherapy.16, 17 Evans and colleagues18 have suggested a new operational definition and pathophysiological mechanisms for cachexia. Low concentrations of testosterone and other anabolic hormones are major contributors to cachexia-related wasting of skeletal muscle and fatigue.18

To our knowledge, no study has systematically reviewed the published work to identify potential clinical associations of androgen deficiency in advanced diseases, such as cancer, where the risk of cachexia is greater. In this qualitative systematic review we aim to assess the published work on the effect of male hypogonadism on functional and nutritional status, symptoms, and quality of life in patients with advanced cancer, and to identify gaps in the knowledge of androgen deficiency diagnosis in advanced cancer for prospective studies.

Section snippets

Search strategy

Publications specifically addressing the relation between male hypogonadism and functional status, nutritional status, body composition, symptoms, and quality of life in patients with advanced cancer were used.

One author (MP) did a review of citations from PubMed (from January, 1966), Medline (from January, 1966), and Embase (from January, 1988) up to March 1, 2009. Keywords included “hypogonadism”, “low testosterone”, “nutritional status”, “body composition”, “quality of life” “function”,

Number and type of studies included

Of 381 potentially relevant unique publications, six were eligible for inclusion in our systematic review (figure 1).5, 16, 17, 19, 20, 21 Some studies were excluded because patients with advanced cancer were not included22, 23, 24 or data on associations between male hypogonadism and clinical outcomes of interest were not reported.25, 26, 27

Population characteristics and measures of hypogonadism

The six reviewed publications included a total of 476 patients (table).5, 16, 17, 19, 20, 21 The most common cancer types assessed were lung and

Discussion

Androgen deficiency has been suggested to be an important contributing factor to cancer cachexia sequelae (eg, muscle wasting and fatigue).18 There is no definitive evidence of an association between male hypogonadism and the nutritional, functional, or quality of life characteristics in patients with advanced cancer. Factors that explain this lack of evidence include heterogeneity of taxonomy, pathophysiology of androgen deficiency in advanced cancer, variation in the normative ranges among

Conclusion

Clear epidemiological data showing whether male hypogonadism is independently associated with clinical and biological sequelae of cancer cachexia (eg, higher inflammation, fatigue, and body wasting) is not available, despite the prevalence of male hypogonadism in patients with advanced cancer16, 17 and the suggested role of androgen deficiency in the pathophysiology of cancer cachexia.18 Furthermore, whether androgen deprivation is merely a cause or a consequence of cancer cachexia is not

References (35)

  • M Johnston et al.

    Construct validation of the hospital anxiety and depression scale with clinical populations

    J Psychosom Res

    (2000)
  • SB Yellen et al.

    Measuring fatigue and other anemia-related syndromes with the Functional Assessment of Cancer Therapy (FACT) measurement system

    J Pain Symptom Manage

    (1997)
  • ME Wierman et al.

    Androgen therapy in women: an endocrine society clinical practice guideline

    J Clin Endocrinol Metab

    (2006)
  • S Bhasin et al.

    Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline

    J Clin Endocrinol Metab

    (2006)
  • KL Becker et al.

    Principles and practice of endocrinology and metabolism

    (2001)
  • JM Garcia et al.

    Hypogonadism in male patients with cancer

    Cancer

    (2006)
  • W de Ronde et al.

    Calculation of bioavailable and free testosterone in Men: a Comparison of 5 Published Algorithms

    Clin Chem

    (2006)
  • Cited by (0)

    View full text